Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results
Belite Bio (NASDAQ: BLTE) will host a live webcast on Monday, November 10, 2025 at 4:30 p.m. ET (1:30 p.m. PT) to discuss third quarter 2025 financial results and provide a business update for the period ended September 30, 2025.
Investors can join at https://events.q4inc.com/attendee/847711723 or via the company’s Investor Relations "Presentations & Events" page. A replay will be available for approximately 90 days after the event.
Belite Bio (NASDAQ: BLTE) terrà un webcast in diretta lunedì 10 novembre 2025 alle 16:30 ET (13:30 PT) per discutere i risultati finanziari del terzo trimestre 2025 e fornire un aggiornamento sull’attività per il periodo terminato il 30 settembre 2025.
Gli investitori possono partecipare all’indirizzo https://events.q4inc.com/attendee/847711723 oppure tramite la pagina delle Relazioni con gli investitori "Presentations & Events" dell’azienda. Una replica sarà disponibile per circa 90 giorni dopo l’evento.
Belite Bio (NASDAQ: BLTE) celebrará un webcast en vivo el lunes 10 de noviembre de 2025 a las 4:30 p.m. ET (1:30 p.m. PT) para discutir los resultados financieros del tercer trimestre de 2025 y proporcionar una actualización comercial para el periodo terminado el 30 de septiembre de 2025.
Los inversores pueden unirse en https://events.q4inc.com/attendee/847711723 o a través de la página de Presentations & Events de Relaciones con Inversores de la empresa. Una retransmisión estará disponible por aproximadamente 90 días después del evento.
Belite Bio (NASDAQ: BLTE)은 2025년 11월 10일 월요일 오후 4:30 ET(태평양 표준시 1:30 PM)에 생방송 웹캐스트를 주최하여 2025년 3분기 재무 실적과 2025년 9월 30일 종료 기간에 대한 사업 업데이트를 논의합니다.
투자자들은 https://events.q4inc.com/attendee/847711723에 참여하거나 회사의 투자자 관계 페이지의 발표 및 이벤트를 통해 참여할 수 있습니다. 이벤트 후 약 90일 동안 재방송이 제공됩니다.
Belite Bio (NASDAQ: BLTE) organisera une webdiffusion en direct le lundi 10 novembre 2025 à 16h30 ET (13h30 PT) pour discuter des résultats financiers du troisième trimestre 2025 et fournir une mise à jour commerciale pour la période se terminant le 30 septembre 2025.
Les investisseurs peuvent se joindre à l’adresse https://events.q4inc.com/attendee/847711723 ou via la page “Presentations & Events” des Relations Investisseurs de l’entreprise. Une rediffusion sera disponible pendant environ 90 jours après l’événement.
Belite Bio (NASDAQ: BLTE) wird am Montag, dem 10. November 2025 um 16:30 Uhr ET (1:30 Uhr PT) einen Live-Webcast veranstalten, um die Ergebnisse des dritten Quartals 2025 zu besprechen und ein Geschäftsupdate für den Zeitraum bis zum 30. September 2025 zu geben.
Investoren können unter https://events.q4inc.com/attendee/847711723 teilnehmen oder über die Seite „Presentations & Events“ der Investor Relations des Unternehmens. Eine Wiedergabe wird ca. 90 Tage nach der Veranstaltung verfügbar sein.
Belite Bio (NASDAQ: BLTE) ستستضيف بثاً مباشراً عبر الويب يوم الإثنين 10 نوفمبر 2025 في الساعة 4:30 مساءً بتوقيت شرق الولايات المتحدة (1:30 مساءً بتوقيت المحيط الهادئ) لمناقشة نتائج الربع الثالث من 2025 وتقديم تحديث أعمال للفترة المنتهية في 30 سبتمبر 2025.
يمكن للمستثمرين الانضمام عبر https://events.q4inc.com/attendee/847711723 أو عبر صفحة العروض والفعاليات في علاقات المستثمرين بالشركة. ستكون هناك إعادة عرض متاحة لما يقرب من 90 يوماً بعد الحدث.
- None.
- None.
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, November 10, 2025, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the third quarter ended September 30, 2025.
Webcast Information
Date: Monday, November 10, 2025
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Webcast Link: https://events.q4inc.com/attendee/847711723
Webcast Link Instructions
You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events. A replay will be available for approximately 90 days after the event.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Julie Fallon
belite@argotpartners.com
FAQ
When will Belite Bio (BLTE) discuss Q3 2025 results?
How can I join the Belite Bio (BLTE) Q3 2025 webcast?
What time is Belite Bio's (BLTE) webcast in Pacific Time?
Will a replay of the Belite Bio (BLTE) Q3 2025 webcast be available?
What will Belite Bio (BLTE) cover during the November 10, 2025 webcast?
